STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
After a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.